AGLARIS LIMITED

Their core work

Aglaris develops automated bioreactor systems for large-scale production of human stem cells and cell therapies. Their core technology is a cell culture platform designed to make advanced therapies like CAR-T affordable and scalable. Starting with automated stem cell production, they have expanded into enabling decentralized, hospital-based manufacturing of personalized cell therapies using digital twins and smart bioprocess control.

What they specialise in

How they've shifted over time

Aglaris began in 2016 with a feasibility study for automated stem cell bioreactors (AGLARIS project), then scaled up in 2019 with a full cell culture platform for affordable cell therapies (Facer). By 2021, they joined the AIDPATH consortium as a third party, shifting toward AI-driven, decentralized production of personalized therapies in hospital settings — adding digital twins, IoT, and machine learning to their bioprocess expertise. The trajectory shows a clear move from hardware-focused bioreactor engineering toward intelligent, software-enabled bioprocessing.

Aglaris is moving from standalone bioreactor hardware toward integrated smart manufacturing systems for personalized medicine, combining their cell culture expertise with AI, digital twins, and IoT — positioning them at the intersection of biotech and Industry 4.0.

How they like to work

Aglaris primarily leads its own projects — coordinating 2 of its 3 H2020 activities, both funded through SME Instruments (Phase 1 and Phase 2), which reflects a self-driven innovation approach typical of deep-tech startups. Their third-party role in AIDPATH (a larger Innovation Action) suggests they are now being sought out by larger consortia for their specialized bioreactor technology. With 14 unique partners across 7 countries, they maintain a reasonably broad network for a small company.

Aglaris has collaborated with 14 unique partners across 7 countries, a solid network for an SME with only 3 projects. Their geographic spread suggests European-wide connections, likely through the AIDPATH consortium which brought them into a larger multi-partner project.

What sets them apart

Aglaris occupies a rare niche at the intersection of bioprocess automation and advanced therapy manufacturing — specifically building the hardware and software that makes cell therapies producible at scale and affordable. Unlike research groups studying cell therapies or large pharma companies producing them, Aglaris focuses on the manufacturing platform itself. For consortium builders, they bring a concrete, product-oriented capability in automated cell production that bridges the gap between lab-scale research and clinical-scale manufacturing.

Highlights from their portfolio

• Facer
  Their largest project (EUR 1.4M, SME Instrument Phase 2) — developed the first cell culture platform for affordable large-scale cell therapy production, representing their core commercial product.
• AIDPATH
  A large collaborative Innovation Action (2021-2025) on AI-driven decentralized therapy production in hospitals, showing Aglaris's technology being integrated into broader smart hospital and digital twin ecosystems.